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Available online 21 May 2016Sister Mary Joseph's nodule is sometimes the ﬁrst sign of an internal malignancy, including gastrointestinal, gy-
necological, or malignancy of unknown primary. It is rarely the sole presentation of a primary peritoneal cancer.
In this report, we present the case of a 70-year-old female with umbilical drainage and a computed tomography
scan consistent with solitary umbilical nodule. Excision of the nodule revealed adenocarcinoma of likely
müllerian origin. Surgical staging did not show any evidence of malignancy with the exception of pelvic wash-
ings. She was considered to have primary peritoneal adenocarcinoma and was treated with adjuvant
chemotherapy.
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Metastatic tumors of the umbilicus are a rare occurrence, ﬁrst de-
scribed by Sister Mary Joseph Dempsey in the early 1900s during her
work with Dr. William James Mayo (Dubreuil et al., 1998). The often
termed Sister Mary Joseph's nodule could be the ﬁrst sign of an internal
malignancy at an advanced stage. It usually presents as a small, ﬁrm
nodule, sometimes with exudates, or as a diffuse induration of the sub-
cutaneous tissue. Differential diagnosis may includemetastasis from in-
ternal malignancy, endometriosis, benign tumors, or primary umbilical
carcinoma. Gastrointestinal malignancy is found in 52% of the metasta-
tic cases and gynecologic and genitourinary origin in 28%, with gastric
and ovarian cancers being themost common (Dubreuil et al., 1998). Al-
though rare, other tumors can also manifest with umbilical metastasis,
including breast and lung cancers, mesothelioma, and multiple myelo-
ma (Dubreuil et al., 1998). However, a primary malignancy is undeter-
mined in approximately 15% of the cases (Dubreuil et al., 1998;
Galvan, 1998; Papalas & Selim, 2011). Metastasis to the umbilicus is
thought to occur via lymphatic channels, venous network, arterial
spread, direct extension from the anterior peritoneal surface, via
embryologic remnants, or in an umbilical hernia, and iatrogenic after
laparoscopy (Dubreuil et al., 1998). However, the exact mode of spread
is not well understood, and direct extension from the anterior peritone-
al surface is thought to be the main route.Oncology, H. LeeMofﬁtt Cancer
edicine, 12902 Magnolia Dr.,
ahzad).
. This is an open access article under2. Case
A 70-year-old female patient initially presented with umbilical
drainage. Computed tomography scan of the abdomen and pelvis was
only relevant for a small umbilical ﬂuid collection. An excision of the
umbilical lesion was performed, and pathology showed metastatic se-
rous carcinoma of müllerian origin. Immunoreactivity stains are
shown in Table 1. PET scan, colonoscopy, esogastroduodenoscopy, and
tumor markers were within normal limits (Table 2).
The patient's past medical history was relevant for an abnormal
mammogram for which she underwent a right breast stereotactic core
biopsy showing intraductal papilloma with ﬂorid ductal hyperplasia
arising in the background of proliferative ﬁbrocystic changes, without
any evidence of malignancy. In addition, she had two episodes of post-
menopausal bleeding with negative hysteroscopy and negative endo-
metrial biopsy.
After referral to our institution, the patient underwent a thorough
physical examination, with normal ﬁndings. A Papanicolaou test
showed rare atypical glandular cells of undetermined signiﬁcance, and
endometrial biopsy was negative for malignancy. Pathology slides
from the Sister Mary Joseph's nodule were reviewed by a pathologist
with expertise in gynecological cancers (Fig. 1). Immunohistochemistry
stains were positive for estrogen receptor, WT-1, PAX-8, CK-7,
pancytokeratins, and had patchy positivity for progesterone receptor.
This was consistent with a tumor of müllerian origin.
Her case was presented at our institutional tumor board, and it was
recommended to proceed with surgery to rule out primary ovarian or
primary peritoneal carcinoma. She underwent an examination under
anesthesia, exploratory laparotomy, total abdominal hysterectomy, bi-
lateral salpingo-oophorectomy, complete omentectomy, and pelvicthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Immunoreactivity of ﬁnal pathology of umbilical lesion biopsy.
Marker Immunoreactivity
Pancytokeratin AE1/AE3 Positive
CK7 Positive
Progesterone receptor Patchy positivity
Estrogen receptor Strong diffusely immunoreactive
WT-1 Strong diffusely immunoreactive
PAX8 Positive
TTF-1 Negative
CDX-2 Negative
CK-20 Negative
Table 2
Serum levels of tumor markers.
Tumor marker Serum level in patient Reference range
CA-125 15.7 U/mL 0–35.0 U/mL
CEA 0.8 ng/mL 0–5.2 ng/mL
CA 27-29 27.9 U/mL 0–38.0 U/mL
AFP 4.4 ng/mL 0–8.3 ng/mL
CA 19-9 9.8 U/mL 0–36.9 U/mL
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cant only for focal serous tubal intraepithelial carcinoma, with no evi-
dence of invasive carcinoma. However, pelvic washings were positive
for adenocarcinoma. The presumed ﬁnal diagnosis was primary perito-
neal carcinoma presenting at the umbilicus, and the recommendation
was for adjuvant chemotherapy with carboplatin and paclitaxel.
3. Discussion
The case outlined in this study demonstrates a rare presentation of
primary peritoneal carcinoma as an umbilical lesion, or Sister Mary
Joseph's nodule. Cases of ovarian and endometrial cancers presentingFig. 1. (A) ×20 magniﬁcation of serous adenocarcinoma found from umbilical nodule. (B) Imm
positive for WT-1.initially as a Sister Mary Joseph's nodule have been previously reported,
but there have been very few cases of a Sister Mary Joseph's nodule as
the initial presentation of primary peritoneal cancer (Galvan, 1998;
Iavazzo et al., 2012).
Most SisterMary Joseph's nodules are umbilicalmetastases from ad-
enocarcinoma followed by squamous cell carcinoma and undifferentiat-
ed tumors. Gastrointestinal malignancy is themost common etiology in
men, whereas gynecological malignancy is the most common etiology
in women, especially ovarian and endometrial malignancies. However,
the primary etiology remains unknown in about 15% to 30% of cases
(Dubreuil et al., 1998; Papalas & Selim, 2011). In a reviewof 77umbilical
tumors identiﬁed over 20 years, Papalas et al. found that 68 (88%) were
metastatic adenocarcinoma, and of these, 58 (85%) were identiﬁed in
the setting of a known primary tumor (Papalas & Selim, 2011). Among
the 10 patients without an assigned primary tumor, 5 had other sites
of metastatic disease, and for 5 the umbilical nodule was the only site
of malignancy identiﬁed. Equally of interest, there were 9 total patients
who presented with an umbilical nodule as the only known site of dis-
ease, of these 3 were ultimately found to have ovarian cancer, and 1
pancreatic cancer, whereas the remaining 5 were designated as un-
known primary (2 poorly differentiated carcinomas, 2 well differentiat-
ed carcinomas, and 1 neuroendocrine tumor). From these data, the
authors conclude that the likelihood of identifying a primary lesion
when presenting with an isolated metastasis to the umbilicus is less
than 50% (Papalas & Selim, 2011).
In the absence of a known primary tumor, diagnosis of Sister Mary
Joseph's nodule is based on histopathological assessment, which can
be followed by targeted physical exam, imaging and biopsies to identify
the primary site. Immunohistochemistry can aid in the diagnosis of
tumor origin in cases of unclear etiology. In this case, the tumor stained
positive for estrogen receptor, progesterone receptor, CK-7, PAX-8, and
WT-1. The ovarian epithelium expresses cytokeratins, including CK-7,
as well as Wilms' tumor gene product (WT1) (Marjoniemi, 2004) Mu-
cinous tumors of müllerian origin tend to express estrogen and proges-
terone receptors (McCluggage, 2012) and PAX-8 is highly expressed in
primary peritoneal serous carcinomas (Kawai et al., 2016). Carcinomaunostaining positive for CK-7. (C) Immunostaining positive for ER. (D) Immunostaining
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al., 2011), which were negative in the case pathology.
The presence of umbilical metastasis usually indicates a poor prog-
nosis. Survival without treatment ranges from 2 to 11 months from
the time of diagnosis. Data have shown improved survival for patients
in whom the umbilical lesion is found before the primary malignancy
in contrast to patients in whom the umbilical lesion is discovered after
treatment for primary malignancy (mean survival of 9.7 months versus
7.6 months, respectively). Some studies have additionally shown im-
proved survival for patients who are treated with a combination of sur-
gery and chemotherapy as opposed to surgery or chemotherapy alone
(Gabriele et al., 2005). Patients who present with isolated umbilical in-
volvement may experience prolonged survival after surgical resection
and appropriate chemotherapy (Galvan, 1998).
Of the cases reviewed in the literature, only one involvingmalignancy
of primary peritoneal origin has been recently reported, by Iavazzo and
associates (Iavazzo et al., 2012); another case was reported by Steck
and colleagues in 1965 (Steck & Helwig, 1965), making this an extremely
rare occurrence. In contrast to the other cases presented in the literature,
the case outlined above describes an umbilical nodule as the sole site of a
primary peritoneal cancer. In cases where histopathology of an umbilical
nodule indicates a serous müllerian tumor, but there is no deﬁnite evi-
dence of a gynecologic primary, we suggest imaging of the chest, abdo-
men and pelvis to evaluate for any other sites of disease, evaluation of
tumor markers including Ca 125, and surgical exploration for both diag-
nosis and cytoreduction. Adjuvant treatment platinum/taxane based che-
motherapy is a reasonable approach and may improve survival.Conﬂict of interest and funding
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